Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy

Clinical Epigenetics

Table 3 Hazard ratios and 95 % confidence intervals for the association of the epigenetic signature with prostate cancer recurrence

Patients	Analysis model	Variables		Recurrence
Patients	Analysis model	Variables		HR	(95 % CI)	P value
All
	Univariate
		Signature (per 25 % increase)		1.78	(1.48, 2.16)	2.05E−09
	Multivariate
		Signature (per 25 % increase)		1.48	(1.21, 1.81)	1.38E−04
		Age (per 1-year increase)		0.98	(0.95, 1.01)	0.21
		Gleason score
			≤6	1.00
			7(3 + 4)	2.25	(1.32, 3.48)	2.89E−03
			7(4 + 3)	5.04	(2.64, 9.65)	1.02E−06
			8–10	4.06	(2.00, 8.26)	1.08E−04
		Pathological stage^a
			Local	1.00
			Regional	2.04	(1.33, 3.14)	1.13E−03
		Diagnostic PSA level (per 1-unit increase)		1.00	(1.00, 1.00)	0.92
Patients with Gleason 7 tumors
	Univariate
		Signature (per 25 % increase)		1.81	(1.42, 2.31)	1.38E−06
	Multivariate
		Signature (per 25 % increase)		1.59	(1.24, 2.05)	3.21E−04
		Age (per 1-year increase)		0.99	(0.95, 1.03)	0.56
		Gleason score
			7(3 + 4)	1.00
			7(4 + 3)	2.08	(1.18, 3.65)	1.09E−02
		Pathological stage^a
			Local	1.00
			Regional	1.82	(1.06, 3.11)	2.94E−02
		Diagnostic PSA level (per 1-unit increase)		1.00	(0.99, 1.01)	0.82
Patients with Gleason 7(3 + 4) tumors
	Univariate
		Signature (per 25 % increase)		1.83	(1.36, 2.45)	5.64E−05
	Multivariate
		Signature (per 25 % increase)		1.65	(1.21, 2.25)	1.54E−03
		Age (per 1-year increase)		1.00	(0.95, 1.05)	0.86
		Pathological stage^a
			Local	1.00
			Regional	1.83	(0.97, 3.45)	0.06
		Diagnostic PSA level (per 1-unit increase)		1.00	(0.99, 1.01)	0.80

ISSN: 1868-7083